U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07067346) titled 'Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma' on June 24.
Brief Summary: Radiopharmaceutical in Relapsed/Refractory Neuroblastoma
Study Start Date: July 18
Study Type: INTERVENTIONAL
Condition:
Neuroblastoma
Intervention:
DRUG: IR-101
IR-101 Dose Escalation
Recruitment Status: RECRUITING
Sponsor: Sichuan University
Information provided by (Responsible Party): Rong Tian, Sichuan University
Published by HT Digital Content Services with permission from Health Daily Digest....